Pharma
Biotechnology, drug development, clinical trials, and healthcare innovation.
Featured Company Videos
Bloomberg|News
CNBC|News
Market Summary
Global Pharma Market: ~$1.5T+ Annual Revenue
FDA Approvals Drive Valuation Inflection Points
Late-Stage Assets Command Premium Multiples
Biotech M&A Remains a Core Growth Engine
Industry Insights
Biotech and pharmaceutical companies operate within a highly regulated, research-driven environment where clinical and regulatory milestones define valuation cycles.
FDA approvals and late-stage trial outcomes serve as primary catalysts, often resulting in rapid market cap expansion or contraction.
Large-cap pharmaceutical companies rely on external innovation through partnerships and acquisitions to sustain long-term growth pipelines.
Patent expiry cycles create recurring revenue pressure, driving reinvestment into next-generation therapies and pipeline development.
Oncology, rare diseases, and precision medicine continue to dominate R&D focus due to strong pricing power and unmet medical demand.
Institutional capital is typically concentrated in companies with advanced clinical assets and clearly defined regulatory pathways.
Industry Leaders
Eli Lilly
LLYGlobal pharmaceutical leader in obesity, diabetes, and oncology.
Novo Nordisk
NVOLeader in diabetes care and GLP-1 therapies.
Johnson & Johnson
JNJDiversified healthcare and pharmaceutical giant.
Merck & Co.
MRKOncology and vaccine powerhouse (Keytruda).
AbbVie
ABBVImmunology and oncology-focused biopharma company.
Amgen
AMGNBiotech leader in biologics and biosimilars.
Gilead Sciences
GILDAntiviral and oncology-focused biotech.
Regeneron Pharmaceuticals
REGNInnovative biotech in immunology and eye care.
Vertex Pharmaceuticals
VRTXLeader in cystic fibrosis and gene-based therapies.
Moderna
MRNAmRNA platform biotechnology company.
Sector Stocks
Replimune Group
REPLOncolytic immunotherapy development.
ORIC Pharmaceuticals
ORICTargeted cancer therapies.
Anixa Biosciences
ANIXCancer immunotherapy and vaccines.
ImmunityBio
IBRXCell-based immunotherapy platform.
Iovance Biotherapeutics
IOVATumor-infiltrating lymphocyte therapies.
Precigen
PGENGene and cell therapy platform.
Exelixis
EXELCancer-focused biotech therapeutics.
Incyte
INCYOncology and inflammation treatments.
BridgeBio Pharma
BBIOGenetic disease therapeutics.
Krystal Biotech
KRYSGene therapy innovation.
Kymera Therapeutics
KYMRTargeted protein degradation platform.
Moderna
MRNAmRNA-based therapeutics and vaccines.
Regeneron Pharmaceuticals
REGNBiologic drug development leader.
Vertex Pharmaceuticals
VRTXGenetic disease therapies.
BioMarin Pharmaceutical
BMRNRare disease treatments.
Alnylam Pharmaceuticals
ALNYRNA interference therapeutics.
Trading Platforms
TradingView
Advanced charting and technical analysis platform.
Interactive Brokers
Global trading across equities, options, and futures.
eToro
Social trading and multi-asset investing platform.
TD Ameritrade
Retail trading with thinkorswim tools.
Charles Schwab
Full-service brokerage and investment platform.
Robinhood
Commission-free trading app for retail investors.
Trade Republic
European mobile-first investing platform offering stocks, ETFs, and savings plans.
Stash
Beginner-friendly investing app with automated portfolios and education tools.
TradeStation
Advanced trading platform with powerful analytics and execution tools.
XS.com
Global multi-asset broker offering forex, commodities, and indices trading.
CityFalcon
AI-driven financial news aggregation and market intelligence platform.
Webull
Mobile-first trading with advanced analytics.
Plus500
CFD trading platform for global markets.
Spotrate Market News
Market News

Emilee Gagliardi: Starting a New Chapter at Merck as a Regional Medical Scientific Director in Breast Oncology
Emilee Gagliardi: Starting a New Chapter at Merck as a Regional Medical Scientific Director in Breast Oncology...

Josep Tabernero GAGO Award
Josep Tabernero receives the Gago Award on European Science Policy for his contribution to advancing European ...
Biosimilars in Bone Metastases: First Real-World Data on Switching
In patients with solid tumours, bone is one of the most frequent sites of metastatic spread. Skeletal involvem...

Biocon Strengthens Oncology Portfolio with Pertuzumab Biosimilar for HER2-Positive Breast Cancer
Biocon Limited has strengthened its oncology portfolio with its pertuzumab biosimilar, intended for use in tre...

Phase II survival results reported for lenvatinib and pembrolizumab in advanced thymic tumors
Final results from the Phase II PECATI clinical trial demonstrate encouraging long-term survival outcomes for ...

Beta Drugs Collaborates With IMGSA Groupe SPA For Oncology Manufacturing In Algeria
Beta Drugs Limited is partnering with IMGSA Groupe SPA for local manufacturing of specialized oncology formula...

Engineered Nanocarriers Shield Therapeutic Probiotics Against Gastrointestinal Degradation in Oncology Trials
A comprehensive scientific review shows engineered nanocarriers preserve over 90 percent of therapeutic probio...

Local oncologist weighs in on ifosfamide, chemotherapy drug shortage
PORTSMOUTH, Va. (WAVY) — Hearing the words, “You have cancer,” can devastate one’s heart and soul. Now imagine...

Kyntra Bio stock pivots after Q3 results, ends oncology programs
Kyntra Bio stock faces a pipeline reset after third-quarter results and the end of two oncology prog...

MAF Test Launches in the US Through NeoGenomics, Challenging Menopause as the Bisphosphonate Gatekeeper
MAF Test Launches in the US Through NeoGenomics, Challenging Menopause as the Bisphosphonate Gatekeeper / Adju...

Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted
Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted / cancer, FDA, ivonescim...

Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?
Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough? / cancer, FDA, H...

Pyxis Oncology’s ADC Shows Potential for Treating Head and Neck Cancer
Pyxis Oncology’s antibody-drug conjugate MICVO shows promising early stage efficacy and manageable safety in a...

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed O...

Imène Hadji: Where is Cancer Immunotherapy Heading?
Imène Hadji: Where is Cancer Immunotherapy Heading? / cancer, colorectal cancer, CS2009, ESMO, esmo 2026, ESMO...

Sergio Cifuentes-Canaval: ctDNA Surveillance in High-Risk ER+/HER2- Early Breast Cancer
Sergio Cifuentes-Canaval: ctDNA Surveillance in High-Risk ER+/HER2- Early Breast Cancer / AFC Okines, Annals o...

Palliative Radiation: Small Treatment, Big Difference
Palliative Radiation: Small Treatment, Big Difference / cancer, India Hub, OncoDaily, Oncology, palliative rad...

OLOL Cancer Institute names new oncology chief
FMOL Health | Our Lady of the Lake Cancer Institute has appointed Dr. Nakhle Saba as its inaugural chief of me...

Servier Shares Extended Follow-Up Data on VORANIGO in IDH-Mutant Glioma
Servier Shares Extended Follow-Up Data on VORANIGO in IDH-Mutant Glioma / glioma, IDH-mutant glioma, Neuro-Onc...

Giuseppe Procopio: New Evidence and Unanswered Questions in Adjuvant Kidney Cancer Treatment
Giuseppe Procopio: New Evidence and Unanswered Questions in Adjuvant Kidney Cancer Treatment / Adjuvant pembro...

Spatial Transcriptomics of TKI Response in Metastatic Clear Cell Renal Cell Carcinoma
Spatial Transcriptomics of TKI Response in Metastatic Clear Cell Renal Cell Carcinoma / cancer, cancer care, C...

Can AI Fix Clinical Trial Access in Oncology? Arturo Loaiza-Bonilla, MD, Built the Answer With the Data to Back It
<div><img src="https://cdn.sanity.io/images/0vv8moc6/onclive/796d06689c57c655e004f731522bfc041d07a462-1280x720...

Onward Therapeutics Raises $28 Million To Advance Oncology Pipeline
Onward Therapeutics has raised NT$900 million, or approximately $28 million, in Series B financing to support ...

Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future Careers
Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and ...

UK: Icon Oncology Group acquires Nova Healthcare
Icon Oncology Group acquires Nova Healthcare...